Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

KyungAh Im

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
European Heart Journal|September 22, 2018
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trialsDavid D Berg, Stephen D Wiviott, Eugene Braunwald, et al.
Circulation|February 15, 2021
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trialsEmily S Lau, Eugene Braunwald, David A Morrow, et al.
JAMA Cardiology|May 23, 2019
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER TrialSabina A Murphy, Terje R Pedersen, Zbigniew A Gaciong, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
Circulation|December 28, 2018
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 TrialBenjamin M Scirica, Erin A Bohula, Jamie P Dwyer, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
European Heart Journal|September 22, 2018
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trialsDavid D Berg, Stephen D Wiviott, Eugene Braunwald, et al.
Circulation|February 15, 2021
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trialsEmily S Lau, Eugene Braunwald, David A Morrow, et al.
JAMA Cardiology|May 23, 2019
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER TrialSabina A Murphy, Terje R Pedersen, Zbigniew A Gaciong, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.
Circulation|December 28, 2018
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 TrialBenjamin M Scirica, Erin A Bohula, Jamie P Dwyer, et al.
Pageof 8